Business
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations AB8939 has dual action against both proliferating tumor cells (via tubulin disru
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS","length":238,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations ","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"AB8939 has dual action against both proliferating tumor cells (via tubulin disruption) and quiescent, resistant stem cells (via ALDH inhibition) making it a unique therapeutic agent","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Based on these findings, AB8939 is being evaluated in a Phase I/II clinical trial for relapsed or refractory AML","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":459,"olType":false},{"type":"text","content":"Paris, December 15, 2025, 6.30pm CET","length":36,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform bioRxiv. This article is entitled ‘Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia’ and is freely accessible online from the bioRxiv website [1].","length":430,"tagName":"p"},{"type":"text","content":"Professor Olivier Hermine, President of AB Science's Scientific Committee, member of the French Academy of Sciences and Head of the Hematology Department at Necker Hosp...